Ticker: ATOS

Atossa Therapeutics, Inc. (NASDAQ: ATOS) Quick read: the company is a clinical‑stage biopharma advancing oral (Z)-endoxifen. It has encouraging clinical signals across multiple trials but is still pre‑revenue, burning cash, facing patent challenges and a Nasdaq minimum‑bid compliance notice. Key ...

Atossa Therapeutics, Inc. (NASDAQ: ATOS) has released its quarterly report for the period ending March 31, 2025. The report highlights continued losses while providing insights into revenue challenges and operational strategies. Key Financial Highlights: Net Loss: $6.7 million for Q1 2025, up fr...